BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24262022)

  • 1. An in vivo mouse model of metastatic human thyroid cancer.
    Zhang L; Gaskins K; Yu Z; Xiong Y; Merino MJ; Kebebew E
    Thyroid; 2014 Apr; 24(4):695-704. PubMed ID: 24262022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kim M; Kim SJ; Xu Z; Ha SY; Byeon JH; Kang EJ; Shin SH; Yoo SK; Jee HG; Yoon SG; Yi JW; Bae JM; Yu HW; Chai YJ; Cho SW; Choi JY; Lee KE; Han W
    Thyroid; 2020 Apr; 30(4):487-500. PubMed ID: 32122255
    [No Abstract]   [Full Text] [Related]  

  • 4. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
    Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
    Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
    Hoelting T; Siperstein AE; Clark OH; Duh QY
    J Clin Endocrinol Metab; 1994 Aug; 79(2):401-8. PubMed ID: 8045955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.
    Morrison JA; Pike LA; Lund G; Zhou Q; Kessler BE; Bauerle KT; Sams SB; Haugen BR; Schweppe RE
    Horm Cancer; 2015 Jun; 6(2-3):87-99. PubMed ID: 25800363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
    Li W; Reeb AN; Sewell WA; Elhomsy G; Lin RY
    PLoS One; 2013; 8(5):e65095. PubMed ID: 23724124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.
    Pringle DR; Vasko VV; Yu L; Manchanda PK; Lee AA; Zhang X; Kirschner JM; Parlow AF; Saji M; Jarjoura D; Ringel MD; La Perle KM; Kirschner LS
    J Clin Endocrinol Metab; 2014 May; 99(5):E804-12. PubMed ID: 24512487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
    Lefley D; Howard F; Arshad F; Bradbury S; Brown H; Tulotta C; Eyre R; Alférez D; Wilkinson JM; Holen I; Clarke RB; Ottewell P
    Breast Cancer Res; 2019 Nov; 21(1):130. PubMed ID: 31783893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A delayed fatal metastatic Hürthle cell carcinoma.
    Noordally SO; Sohawon S; Duttmann R; Spinato L; Kleynen P; Verougstraete G
    Acta Medica (Hradec Kralove); 2011; 54(2):87-9. PubMed ID: 21842725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
    Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
    Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
    Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
    Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
    Antonello ZA; Nucera C
    Oncogene; 2014 Nov; 33(47):5397-404. PubMed ID: 24362526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel orthotopic mouse model of human anaplastic thyroid carcinoma.
    Nucera C; Nehs MA; Mekel M; Zhang X; Hodin R; Lawler J; Nose V; Parangi S
    Thyroid; 2009 Oct; 19(10):1077-84. PubMed ID: 19772429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.